Metacrine Reports Third-Quarter 2021 Results
11 nov. 2021 08h00 HE
|
Metacrine, Inc.
SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and...
Metacrine Reports Interim Results for MET642 Phase 2a Trial in Patients with NASH and Announces a Strategic Re-Prioritization of Its Clinical Development Programs
21 oct. 2021 16h01 HE
|
Metacrine, Inc.
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis
14 oct. 2021 09h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 14, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
21 sept. 2021 12h47 HE
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development...
Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash
09 sept. 2021 08h05 HE
|
Metacrine, Inc.
Exceeded enrollment target of 180 total patientsInterim data from the first 60 patients expected early in the fourth quarter of 2021Topline MET642 trial results from all patients are anticipated in...
Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021
08 sept. 2021 08h05 HE
|
Metacrine, Inc.
Featuring KOL and management discussions on the science of FXR agonists and the Company’s programs in NASH and IBD SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a...
Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 08h05 HE
|
Metacrine, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
12 août 2021 08h05 HE
|
Metacrine, Inc.
Interim data from the Phase 2a trial of MET642 in patients with NASH now expected early in the fourth quarter of 2021Topline results from a Phase 2a trial of MET409 in combination with empagliflozin...
FDA Grants Vitality Biopharma Orphan Drug Designation for VBX-100 Prodrug
10 août 2021 09h00 HE
|
Vitality Biopharma, Inc
CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic...
Metacrine to Present at 2021 Canaccord Genuity Growth Conference
09 août 2021 08h05 HE
|
Metacrine, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...